Evidence map›Paper›PMID 41028548›Full record

ArticleMedical oncology (Northwood, London, England)2025

LncRNA LOXL1-AS1 promotes ovarian cancer progression by enhanced BRIP1 mRNA stability.

Su Wan, Chang Su, Jin Ding, Ji Liu, Lingli He, Lifen Liu, Qi Peng, Guantai Ni, Weipei Zhu

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Su WanDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Soochow University, Gusu District, No.1055, Sanxiang Road, Suzhou, 215000, China.
Chang SuDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Wannan Medical College, No.2, Zheshan West Road, Wuhu, 241000, China.
Jin DingDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Wannan Medical College, No.2, Zheshan West Road, Wuhu, 241000, China.
Ji LiuDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Wannan Medical College, No.2, Zheshan West Road, Wuhu, 241000, China.
Lingli HeDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of Wannan Medical College, No.2, Zheshan West Road, Wuhu, 241000, China.
Lifen LiuDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Soochow University, Gusu District, No.1055, Sanxiang Road, Suzhou, 215000, China.
Qi PengDepartment of Obstetrics and Gynecology, Jiangdu People's Hospital of Yangzhou, No.100, Jiangzhou Road, Yangzhou, 225000, China.
Guantai Ni *Department of Obstetrics and Gynecology, The First Affiliated Hospital of Wannan Medical College, No.2, Zheshan West Road, Wuhu, 241000, China. niguantai@wnmc.edu.cn.
Weipei Zhu *Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Soochow University, Gusu District, No.1055, Sanxiang Road, Suzhou, 215000, China. zwp3333@suda.edu.cn.

Funding

Health research project of Anhui Province cancer prevention special AHWJ2023BBa20063National Natural Science Foundation of China 82201820Wuhu City key development and scientific and technological achievements transformation project 2023yf082
6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) have crucial effects on the development of malignant tumors. This work focused on determining how LOXL1-AS1 contributed to epithelial ovarian cancer development. As indicated by quantitative RT-polymerase chain reaction (qRT-PCR), LOXL1-AS1 showed significant overexpression within ovarian epithelial cancer tissues and ovarian cancer cells compared with non-cancer samples and regular human epithelial cell lines. According to CCK-8, flow cytometry, plate cloning, cell scratch test, a series of cell function tests in vitro, a nude mouse transplanted tumor model, and Western blot assays, LOXL1-AS1 siRNA transfection suppressed the growth, invasion, and epithelial-to-mesenchymal transformation characteristics of SKOV3 and A2780 cells in vitro and vivo. As discovered, LOXL1-AS1 targets BRCA1-interacting protein C-terminal helicase 1 (BRIP1) mRNA, resulting in a malignant phenotype of ovarian cancer. Overexpression of BRIP1 reversed the inhibition of cell progression induced by LOXL1-AS1 siRNA. In addition, based on RNA stability experiments, LOXL1-AS1 enhanced ovarian cancer cell growth and metastasis by stabilizing BRIP1 mRNA. Our findings reveal a novel mechanism of how LOXL1-AS1 enhances epithelial ovarian cancer progression by specifically regulating BRIP1 mRNA stability. This provides the potential therapeutic application of LOXL1-AS1 targeting BRIP1 for treating ovarian cancer.

Indexed as

Amino Acid OxidoreductasesCarcinoma, Ovarian EpithelialFanconi Anemia Complementation Group ProteinsOvarian NeoplasmsRNA-Binding ProteinsRNA HelicasesRNA, Long NoncodingRNA StabilityAnimalsCell Line, TumorCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansAmino Acid OxidoreductasesBRIP1 protein, humanFanconi Anemia Complementation Group ProteinsLOXL1 protein, humanRNA-Binding ProteinsRNA HelicasesRNA, Long NoncodingRNA, MessengerBRIP1LOXL1-AS1mRNA stabilityOvarian cancer

Identifiers

PMID41028548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.